Provided by Tiger Trade Technology Pte. Ltd.

Crinetics Pharmaceuticals Inc.

84.95
0.0000
Volume:- -
Turnover:697.41M
Market Cap:9.01B
PE:-16.89
High:84.95
Open:84.95
Low:84.95
Close:84.95
52wk High:85.01
52wk Low:31.00
Shares:106.10M
Float Shares:95.53M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0290
EPS(LYR):-4.9500
ROE:-42.45%
ROA:-26.28%
PB:7.56
PE(LYR):-17.16

Loading ...

Jun 22, 2023

Major Issues Report

Form 8-K - Current report
Jun 20, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 16, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 04, 2023

Major Issues Report

8-K - Current report
Mar 15, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 13, 2023

Major Issues Report

8-K - Current report
Feb 28, 2023

Major Issues Report

8-K - Current report
Feb 28, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 28, 2023

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 14, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 19, 2023

Correspondence

CORRESP [Cover] - Correspondence
Jan 09, 2023

Major Issues Report

8-K - Current report
Nov 28, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]